Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study on optimal therapy duration of oral angiogenesis inhibitors
2008-002672-95Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sorafenib and sunitinib in Non-hematologic malignancy, sponsored by Radboud University Medical Center. Primary endpoints: Frequency of rapid disease and symptom increase after stopping therapy and Predictors of rapid disease and symptom increase after stopping therapy. Started Jun 2008; status: completed.
02
Drugs
sorafenibsunitinib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2008-002672-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002672-95.